Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- NBI Files Additional Indication of Asthma for Spiriva
January 7, 2014
- Eisai Launches Epilepsy Treatment Fycompa in US
January 7, 2014
- Astellas to Transfer Fermentation Research-Related Assets to Taiho
January 7, 2014
- New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
- Azilva Tops SOC Ranking for Second Month in a Row in November in Both Hospital and GP Markets: Anterio
January 6, 2014
- Novartis Seeks Japanese Regulatory Approval of Psoriasis Agent Secukinumab
January 6, 2014
- Shionogi, AZ Revise Royalty Rate for Crestor
January 6, 2014
- Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
- Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
- Ono Files NDA for Nivolumab for Malignant Melanoma
December 27, 2013
- MSD Files NDA for Vaniprevir for Chronic Hepatitis C
December 27, 2013
- Kissei Grants US Pfizer Worldwide Exclusive Rights for Gout and Hyperuricemia Treatment KUX-1151 Outside Japan
December 26, 2013
- Meiji Seika Pharma Scraps Codevelopment Deal with Danish Biotech
December 26, 2013
- Takeda to License Inflammatory Bowel Disease Treatment from US Biotech
December 25, 2013
- Tenelia Now Indicated for Type 2 Diabetes Without Concurrent Use Restrictions
December 25, 2013
- SSI Said Ex-Employee Manipulated Data of Anti-Obesity Drug Study
December 25, 2013
- Daiichi Sankyo Files Edoxaban for AF, VTE New Indications
December 25, 2013
- Kyowa Kirin, LEO Pharma Collaborate to Market Fixed-Dose Combination Topical Treatment for Psoriasis in Japan
December 24, 2013
- Shire Names NBI Operating Officer Sunohara as New Japan Head
December 20, 2013
- Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…